Adam Hartigan

Adam Hartigan has a diverse work experience in the biotechnology industry, with a focus on hematology and immunotherapy. Adam is currently working at Beam Therapeutics as the Vice President and Program Leader for Hematology since January 2023. Prior to their current role, they held the position of Head of Hematology at Beam Therapeutics from July 2019 to February 2023. Before joining Beam Therapeutics, Adam worked as an Associate Director of Translational Biology at FogPharma from February 2018 to June 2019. Adam also served as a Senior Scientist II in HSC Biology at Magenta Therapeutics from 2016 to 2018 and as a Senior Scientist in Immunotherapy at Merck from 2014 to 2016. Adam's career started with a postdoctoral fellowship at Harvard University and Joslin Diabetes Center, where they worked from 2010 to 2014.

Adam Hartigan received a Bachelor of Science degree in Biochemistry from SUNY Geneseo in 2003. Adam then went on to pursue a PhD in Immunology at the University of Michigan, completing their studies in 2009.